February 6, 2025 14:45

Six years after acquiring Milacron, Hillenbrand has announced the sale of a majority stake in the injection molding and extrusion machinery maker to Bain Capital under an agreement signed on Feb. 5.

As part of the deal, Hillenbrand will transfer 51% of Milacron Injection Molding & Extrusion to Bain Capital for $287 million while retaining a 49% stake in the company.
The net proceeds from the transaction, estimated at $250 million, will be used to reduce debt.

In 2024, Milacron reported $526 million in revenue and an adjusted EBITDA of $64 million. Founded in 1960, the company operates with two production facilities, one in the United States and another in India. It is currently part of Hillenbrand’s Molding Technology Solutions (MTS) segment, alongside Mold-Masters (hot runner systems) and DME (molds and tooling components).

The acquisition is being carried out by Bain Capital Special Situations, an affiliate that recently closed its second fundraising cycle, securing over $9 billion.
The transaction is expected to close by the end of Hillenbrand’s fiscal second quarter or the beginning of the third, subject to customary closing conditions.

"Milacron is an iconic American manufacturing business with a 50-year legacy of driving innovation in plastics," said Matt Evans, partner at Bain Capital Special Situations. "With manufacturers increasingly focused on supply-chain resilience and domestic production, we believe the U.S. is entering a manufacturing renaissance that will create significant opportunities for industry leaders like Milacron. With its advanced engineering capabilities, global reach, and deep customer relationships, Milacron is well-positioned to build on its strong foundation."

© Polimerica -  Reproduction prohibited, all rights reserved